Biotech


  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Emerging biotech

    Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

    It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company has acquired a portfolio of medicines it aims to test in combination.

    By April 18, 2024
  • An illustration of two neurons, colored blue and purple
    Image attribution tooltip
    noparrit via Getty Images
    Image attribution tooltip

    Sage’s cognition drug fails in Parkinson’s study

    Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

    By April 17, 2024
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • A portrait of Uwe Schoenbeck at Canaan Partners.
    Image attribution tooltip
    Permission granted by Canaan
    Image attribution tooltip

    Canaan hires Pfizer executive, reels in $100M for biotech investing

    The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.

    By April 17, 2024
  • An illustration of antibodies attacking a nerve cell.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Cullinan changes name, pivots to autoimmune disease

    The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.

    By Kristin Jensen • April 16, 2024
  • Two people in white coats work at a laboratory benchtop.
    Image attribution tooltip
    Courtesy of Alexandria Real Estate Equities
    Image attribution tooltip
    Q&A // Emerging biotech

    Biotech landlord Alexandria on research clusters and the sector’s recovery

    Joel Marcus, the longtime head of Alexandria Real Estate Equities, sees few near-term challengers to the established biotech hubs of Boston, San Diego and San Francisco.

    By April 16, 2024
  • Neumora CEO Henry Gosebruch stands for a photo against a blurred office background
    Image attribution tooltip
    Permission granted by Neumora Therapeutics
    Image attribution tooltip

    Neumora’s schizophrenia drug hit with clinical hold

    Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.

    By April 15, 2024
  • Regeneron commits $500M to new venture capital fund

    While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.

    By April 15, 2024
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Biotech IPOs bounced back in first quarter, but backlog remains

    Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show.

    By April 12, 2024
  • NK Cell (Natural Killer Cell) Attacking a Cancer Cell
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Emerging biotech

    Century buys a startup, raises funding in cell therapy expansion

    The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.

    By April 11, 2024
  • A pregnant person is checked with a stethoscope in a doctor's office.
    Image attribution tooltip
    PeopleImages via Getty Images
    Image attribution tooltip

    J&J, Rallybio partner on drug development for rare fetal condition

    The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

    By April 10, 2024
  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    whitehoune via Getty Images
    Image attribution tooltip
    Emerging biotech

    PureTech launches Seaport, hoping to create Karuna 2.0

    The startup is taking aim at anxiety with $100 million from high-profile biotech backers like ARCH, Sofinnova and Third Rock.

    By April 9, 2024
  • Two people in white coats work at a laboratory bench.
    Image attribution tooltip
    Adene Sanchez via Getty Images
    Image attribution tooltip

    Private biotech funding rises as venture firms deploy cash

    Twenty-six drugmakers closed fundraising rounds worth more than $100 million in the first quarter, according to HSBC data shared with BioPharma Dive.

    By April 8, 2024
  • A person wearing a white coat works at a research laboratory bench.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Deep Dive

    Psychiatry drugs finally have pharma’s attention. Can they keep it?

    Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.

    By April 8, 2024
  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    Emerging biotech

    Contineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs

    The offering keeps new biotech stock offerings on their strongest pace in three years, accompanying an uptick in private company funding.

    By April 4, 2024
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx to pull ALS drug from market in rare move

    In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.

    By April 4, 2024
  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    JaysonPhotography via Getty Images
    Image attribution tooltip

    Paragon’s hub-and-spoke biotech model yields another reverse merger

    Oruka Therapeutics is the third startup from Paragon to go public since last year, and the second to do so by combining with another biotech.

    By April 3, 2024
  • A 3D visualization of red blood cells traveling through a blood vessel.
    Image attribution tooltip
    Kahan Shan via Getty Images
    Image attribution tooltip
    Emerging biotech

    Diagonal starts up with $128M to make better ‘activator’ antibody drugs

    The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

    By April 3, 2024
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Roivant reveals positive immune drug data, share buyback plans

    A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

    By April 2, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Acorda files for bankruptcy, reveals asset sale plan

    Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

    By April 2, 2024
  • Brain investment
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    A dementia-focused VC digs past amyloid for new kinds of brain drugs

    The Dementia Discovery Fund set out to spark research into new approaches for diseases like Alzheimer’s, even as anti-amyloid therapies reach patients.

    By Michael Gibney • April 2, 2024
  • An illustration of immune system T cells attacking cancer cells.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Ginkgo, in search of more cell therapy tools, buys another startup

    A deal for Modulus Therapeutics is the latest move by Ginkgo to accumulate technologies that can help other companies develop cellular medicines.

    By April 2, 2024
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex moves kidney disease drug into late-stage testing

    The drug, inaxaplin, is an important pipeline prospect for Vertex, which is working to expand beyond the cystic fibrosis medicines that made its name. 

    By April 1, 2024
  • An illustration of a stock market graph and bar chart price display.
    Image attribution tooltip
    maciek905 via Getty Images
    Image attribution tooltip
    Emerging biotech

    Boundless Bio breaks IPO lull with $100M fundraise

    The startup’s performance will test investors’ appetite for early-stage drugmakers, as Boundless has only advanced as far as Phase 1 clinical trials.

    By March 28, 2024
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead bets on Xilio cancer drug as biotech restructures

    Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.

    By March 28, 2024
  • A person in hiking gear stands for a photograph with mountains in the background.
    Image attribution tooltip
    Permission granted by Art Krieg
    Image attribution tooltip
    Emerging biotech

    Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup

    With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Dive.

    By March 28, 2024